AVEO Pharma (AVEO) to Present Data from Tivozanib at AACR 12

March 27, 2012 6:37 AM EDT Send to a Friend
AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, and preclinical data on AV-203, AVEO’s ErbB3 inhibitory antibody, will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2012 being held March 31-April 4, 2012 in Chicago.

For the schedule, click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment